Not available
Quote | FibroGen Inc (NASDAQ:FGEN)
Last: | $1.07 |
---|---|
Change Percent: | -0.88% |
Open: | $1.15 |
Close: | $1.07 |
High: | $1.26 |
Low: | $1.05 |
Volume: | 1,337,984 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | FibroGen Inc (NASDAQ:FGEN)
2024-04-03 15:54:24 ET More on FibroGen FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript AstraZeneca returns right to roxadustat to FibroGen Seeking Alpha’s Quant Rating on FibroGen ...
2024-04-03 10:00:34 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
Message Board Posts | FibroGen Inc (NASDAQ:FGEN)
Subject | By | Source | When |
---|---|---|---|
2.67 AH | TheFinalCD | investorshub | 06/26/2023 9:33:33 PM |
dead cat bounce? | nuclear profitz | investorshub | 06/26/2023 2:10:27 PM |
$FGEN just the news we needed | DewDiligence | investorshub | 06/24/2023 7:17:49 AM |
$FGEN Good news recently, we should start to see this one move | MikeBK205 | investorshub | 06/23/2023 11:53:12 PM |
Thoughts on where this is headed? | SealTheDeal | investorshub | 06/22/2023 1:10:34 AM |
News, Short Squeeze, Breakout and More Instantly...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...
FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a pot...
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free survival of 8.7 months PSA50 response in 36% ...